Talking about growth. Two stories that are very compelling & can help streamline the drug discovery process in bio-tech are $BLI & $SDGR. They both took an absolute killing these past few weeks, yet still trade high to their forward revenue multiples (21'/22'). With that said they do provide a need in the industry, and have a competitive/first-mover advantage.